“Globally, we surpassed 500,000 patients treated with a Watchman device driven by our innovation, clinical evidence and patient-awareness efforts,” Mahoney said. Boston Scientific’s business ...

Analyst Mike Matson highlighted that the growth story for Boston Scientific depends heavily on its cardiac implant, Watchman. Watchman is a medical device that's effectively designed to reduce the ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers ... We remain bullish on the Watchman left atrial appendage closure franchise (despite ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

J.P. Morgan analysts are looking for heart device Watchman to contribute this quarter and accelerate if its label is expanded next year. Boston Scientific is also set to share transcatheter aortic ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...